MIRAAnother lap around the clinical track
MIRA Pharmaceuticals just gave Ketamir-2 a little more runway. After getting review and comments from the FDA, the company submitted its Phase 2a protocol for Institutional Review Board review at a leading cancer research institution.
That may sound like biotech paperwork bingo, but it’s actually the kind of incremental progress investors like to see. In biotech, forward motion matters because every regulatory checkpoint cleared is one less excuse for a program to stall out in the mud.
Why this matters
Ketamir-2 is being tested in chemotherapy-induced peripheral neuropathy, or CIPN — the painful nerve damage that can follow cancer treatment. If MIRA can show this drug helps patients here, that would open the door to a potentially meaningful niche with real medical need.
What you should keep an eye on:
- FDA feedback is already in the rearview mirror, at least for this protocol phase
- IRB review is the next gate before the study can move ahead
- Phase 2a data is the thing investors will eventually care about, because that’s where the story either starts to look promising or gets much more complicated
Big picture
This isn’t blockbuster revenue news, and it won’t pay the bills tomorrow. But for a clinical-stage company, keeping a program advancing — instead of frozen in regulatory limbo — is the whole game.